CLINICAL TRIALS PROFILE FOR CABENUVA KIT
✉ Email this page to a colleague
All Clinical Trials for CABENUVA KIT
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT04982445 ↗ | Study Using CABENUVA™ for the Treatment of Human Immunodeficiency Virus (HIV)-1, Administered in Infusion Centers (IC) in the United States (U.S.) | Not yet recruiting | ViiV Healthcare | Phase 4 | 2021-10-29 | GLACIER (Giving Long Acting CABENUVA in an Infusion centER) is an interventional study examining the administration of CABENUVA (Cabotegravir long acting [LA] plus Rilpivirine LA) intramuscular (IM) in infusion centers in South-eastern United States. In this study, the intervention is the process of using an infusion center as the location to receive the CABENUVA IM injections. The acceptability and feasibility of the IC to deliver CABENUVA IM injections will be assessed from the perspectives of the participants, HIV care providers and IC staff. In this study, Month 1 is the Baseline visit. CABENUVA is a registered trademark of ViiV Healthcare. |
| NCT05601128 ↗ | A Study Evaluating the Pharmacokinetics, Efficacy, Safety and Tolerability of CABENUVA | Not yet recruiting | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | Phase 3 | 2023-01-01 | The purpose of this study is to evaluate the efficacy and safety of CABENUVA (Long-acting Cabotegravir Plus Long-acting Rilpivirine) in patients with HIV infection and severe renal impairment. This study is considered research and is voluntary. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for CABENUVA KIT
Condition Name
Clinical Trial Locations for CABENUVA KIT
Trials by Country
Clinical Trial Progress for CABENUVA KIT
Clinical Trial Phase
Clinical Trial Sponsors for CABENUVA KIT
Sponsor Name
